SARS-CoV-2-Specific Human Neutralizing Monoclonal Antibody Development Service

SARS-CoV-2-Specific Human Neutralizing Monoclonal Antibody Development Service

SARS-CoV-2 Nucleocapsid Rabbit Monoclonal Antibody Development Service

SARS-CoV-2 Nucleocapsid Rabbit Monoclonal Antibody Development Service

SARS-CoV-2 Spike S1 Rabbit Monoclonal Antibody Development Service

SARS-CoV-2 (2019-nCoV) spike RBD human monoclonal antibody is in stock. SARS-CoV-2-specific human neutralizing monoclonal antibody development service and SARS-CoV-2 nucleocapsid rabbit monoclonal antibody development service are available.

Grouped product items
Product Name Quantity
SARS-CoV-2 Spike S1 Rabbit Monoclonal Antibody Development Service (Catalog No.: BS091)

BS091: SARS-CoV-2 Spike Protein S1 Subunit Rabbit Monoclonal Antibody Development Service

We immunized rabbits with SARS-CoV-2 S protein S1 subunit, then did single B cell sorting and culturing. There will be about 70 ul supernatant per well (clonal single B cell). If you are interested in rabbit monoclonal antibodies against SARS-CoV-2 Spike protein especially the S1 subunit or RBD (receptor binding domain), we can send you some supernatant for quick screening. Then you tell us which single B cell clone you like. We sequence the antibody VH/VL and produce recombinant rabbit single B cell for your confirmation. You can pay for the antibody or the clone with discount or exclusive right.

To know more about our rabbit monoclonal antibody development services, please visit:

Rabbit monoclonal antibody development services
Single B cell antibody cloning and sequencing services


The S1 subunit of the SARS-CoV-2 (2019-nCoV) spike (S) glycoprotein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of virus entry inhibitors, neutralizing antibodies, and vaccines. There are two subunits, S1 and S2, in the SARS-CoV-2 spike (S) glycoprotein. The S1 subunit, the N-terminal 14–685 amino acids of S protein, contains N-terminal domain (NTD), receptor binding domain (RBD), and receptor binding motif (RBM). The SARS-CoV and SARS-CoV-2 S proteins mediate viral entry into host cells by binding to a host receptor, angiotensin-converting enzyme 2 (ACE2), through RBD in the S1 subunit, and then fusing the viral and host membranes through the S2 subunit.

The SARS-CoV-2 S1 subunit especially its RBD has become a popular target of antibodies for diagnostics test and proteins and antibodies for therapeutic drugs. The amino-acid sequence identity is around 74% between the RBDs in the SARS-CoV and SARS-CoV-2 spike proteins, similar to the 77% identity between the whole spike proteins of SARS-CoV and SARS-CoV-2. Such a high degree of sequence similarity raises the possibility that cross-reactive epitopes may exist. Although the SARS-CoV RBD polyclonal antibodies can recognize both viruses, it was reported that only one published RBD monoclonal antibodies neutralizing SARS-CoV bound to SARS-CoV-2 spike RBD. Out of the 28 residues in the epitope of the S1 RBD monoclonal antibody, only 4 residues (86%) in SARS-CoV-2 are different from SARS-CoV. However, the S1 RBD mAb binds to SARS-CoV spike RBD (Kd = 1 nM) with a much higher affinity than to SARS-CoV-2 spike RBD (Kd = 115 nM, or 6.3 nM measured by another lab). Thus, it is important and possible to develop SARS-CoV-2 specific monoclonal antibodies using SARS-CoV-2 Spike protein, its S1 subunit, or RBD with binding and even neutralizing functions.

To check more Syd Labs SARS-CoV-2 (2019-nCoV) Antigen and Antibody Reagents and Discovery Services

Questions and Answers:

Question: Is SARS-CoV-2 spike protein S1 subunit or its RBD a better immunogen for antibody development?
Answer: S1 subunit is better since it is bigger with more potential epitopes possibly better for neutralizing antibody development. Even for RBD, some antibodies binds to RBD but does not block the interaction between RBD and the receptor ACE2.

Question: Do you deliver a cell line like hybridoma?
Answer: No, the rabbit monoclonal antibody sequences (VH and VL) or plasmid DNAs will be delivered. Clients can use them to produce recombinant rabbit monoclonal antibodies in HEK 293 or CHO cells.

Question: What is the advantage of your rabbit monoclonal antibody screening method against other single B cell-based rabbit monoclonal antibody development methods?
Answer: Using the strategy without culturing, one may screen antibodies from hundreds of single B cells after a lot of efforts; however, one may easily screen antibodies from thousands of cultured single B cells.

Question: Is the license fee expensive if I want to own the clone sequences after screening?
Answer: Clients just need to pay the license fee as a custom rabbit monoclonal antibody development service no matter how many clones you will select in the end. The number of single B cells to screen from beginning matters.

Write Your Own Review
Only registered users can write reviews. Please Sign in or create an account